@article{fdi:010074806,
  title = {{T}enofovir exposure during pregnancy and postpartum in women receiving tenofovir disoproxil fumarate for the prevention of mother-to-child transmission of hepatitis {B} virus},
  author = {{C}ressey, {T}. {R}. and {H}arrison, {L}. and {A}chalapong, {J}. and {K}anjanavikai, {P}. and {A}yudhaya, {O}. {P}. {N}. and {L}iampongsabuddhi, {P}. and {S}iriwachirachai, {T}. and {P}utiyanun, {C}. and {S}uriyachai, {P}. and {T}ierney, {C}. and {S}alvadori, {N}icolas and {C}hinwong, {D}. and {D}ecker, {L}uc and {T}awon, {Y}. and {M}urphy, {T}. {V}. and {N}go-{G}iang-{H}uong, {N}icole and {S}iberry, {G}. {K}. and {J}ourdain, {G}onzague and i{TAP} {S}tudy {T}eam},
  editor = {},
  language = {{ENG}},
  abstract = {{W}e assessed tenofovir exposure during pregnancy and postpartum in hepatitis {B} virus ({HBV})-infected {HIV}-uninfected women receiving tenofovir disoproxil fumarate ({TDF}) to prevent mother-to-child transmission of {HBV}. {D}ata from 154 women who received {TDF} within a randomized controlled trial were included. {I}ndividual plasma tenofovir exposures (area under the concentration-time curve from 0 to 24 h [{AUC}0-24]) were estimated using a population pharmacokinetic approach. {T}he estimated geometric mean tenofovir {AUC}(0-24) was 20% (95% confidence interval [95% {CI}], 19 to 21%) lower during pregnancy than during postpartum; this modest reduction in the absence of {HBV} transmission suggests that no dose adjustment is needed.},
  keywords = {pregnancy ; tenofovir ; hepatitis {B} virus ; pharmacokinetics ; {THAILANDE}},
  booktitle = {},
  journal = {{A}ntimicrobial {A}gents and {C}hemotherapy},
  volume = {62},
  numero = {12},
  pages = {e01686--18 [5 p.]},
  ISSN = {0066-4804},
  year = {2018},
  DOI = {10.1128/aac.01686-18},
  URL = {https://www.documentation.ird.fr/hor/fdi:010074806},
}